PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-22.03%
Negative EBIT growth while TRAW is at 3.51%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-22.03%
Negative operating income growth while TRAW is at 3.51%. Joel Greenblatt would press for urgent turnaround measures.
-22.30%
Negative net income growth while TRAW stands at 18.00%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-22.29%
Negative EPS growth while TRAW is at 34.62%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-22.29%
Negative diluted EPS growth while TRAW is at 34.62%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-72.30%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-72.45%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-22389.18%
Negative 10Y OCF/share CAGR while TRAW stands at 90.77%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
42.89%
Below 50% of TRAW's 95.97%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
64.68%
3Y OCF/share CAGR at 50-75% of TRAW's 91.99%. Martin Whitman would suspect weaker recent execution or product competitiveness.
-7255.64%
Negative 10Y net income/share CAGR while TRAW is at 95.19%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-121.67%
Negative 5Y net income/share CAGR while TRAW is 96.50%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
22.78%
Below 50% of TRAW's 94.09%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
5223.15%
Equity/share CAGR of 5223.15% while TRAW is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
855.06%
Positive 5Y equity/share CAGR while TRAW is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-50.27%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.46%
Asset growth at 50-75% of TRAW's 73.03%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
59.08%
1.25-1.5x TRAW's 49.53%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
15.66%
R&D growth drastically higher vs. TRAW's 2.21%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
40.35%
SG&A growth well above TRAW's 6.00%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.